Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Letizia Foroni

Showing results (41-50 of 84) with videos related to

Pageof 9
Sort By:
American Journal of Hematology|February 18, 2011
Duplex quantitative PCR for molecular monitoring of BCR-ABL1-associated hematological malignanciesGareth Gerrard, Katherine Mudge, Rebecca Stewart, et al.
American Journal of Hematology|September 25, 2014
PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phaseJuan M Alonso-Dominguez, Jacob Grinfeld, Mary Alikian, et al.
British Journal of Haematology|May 31, 2013
Target enrichment and high-throughput sequencing of 80 ribosomal protein genes to identify mutations associated with Diamond-Blackfan anaemiaGareth Gerrard, Mikel Valgañón, Hui En Foong, et al.
The Lancet. Haematology|June 2, 2017
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trialRichard E Clark, Fotios Polydoros, Jane F Apperley, et al.
Clinical Chemistry|December 17, 2016
RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid LeukemiaMary Alikian, Alexandra S Whale, Susanna Akiki, et al.
The Journal of Molecular Diagnostics : JMD|February 10, 2016
Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia PatientsMary Alikian, Peter Ellery, Martin Forbes, et al.
Oncotarget|February 13, 2016
The status of epidermal growth factor receptor in borderline ovarian tumoursRania Showeil, Claudia Romano, Mikel Valganon, et al.
British Journal of Haematology|October 30, 2009
Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993Bella Patel, Lena Rai, Georgina Buck, et al.
American Journal of Hematology|January 11, 2012
BCR-ABL1 kinase domain mutations: methodology and clinical evaluationMary Alikian, Gareth Gerrard, Papagudi G Subramanian, et al.
The Lancet. Haematology|June 16, 2019
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trialRichard E Clark, Fotios Polydoros, Jane F Apperley, et al.
Pageof 9

Showing results (41-50 of 84) with videos related to

Sort By:
Pageof 9
American Journal of Hematology|February 18, 2011
Duplex quantitative PCR for molecular monitoring of BCR-ABL1-associated hematological malignanciesGareth Gerrard, Katherine Mudge, Rebecca Stewart, et al.
American Journal of Hematology|September 25, 2014
PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phaseJuan M Alonso-Dominguez, Jacob Grinfeld, Mary Alikian, et al.
British Journal of Haematology|May 31, 2013
Target enrichment and high-throughput sequencing of 80 ribosomal protein genes to identify mutations associated with Diamond-Blackfan anaemiaGareth Gerrard, Mikel Valgañón, Hui En Foong, et al.
The Lancet. Haematology|June 2, 2017
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trialRichard E Clark, Fotios Polydoros, Jane F Apperley, et al.
Clinical Chemistry|December 17, 2016
RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid LeukemiaMary Alikian, Alexandra S Whale, Susanna Akiki, et al.
The Journal of Molecular Diagnostics : JMD|February 10, 2016
Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia PatientsMary Alikian, Peter Ellery, Martin Forbes, et al.
Oncotarget|February 13, 2016
The status of epidermal growth factor receptor in borderline ovarian tumoursRania Showeil, Claudia Romano, Mikel Valganon, et al.
British Journal of Haematology|October 30, 2009
Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993Bella Patel, Lena Rai, Georgina Buck, et al.
American Journal of Hematology|January 11, 2012
BCR-ABL1 kinase domain mutations: methodology and clinical evaluationMary Alikian, Gareth Gerrard, Papagudi G Subramanian, et al.
The Lancet. Haematology|June 16, 2019
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trialRichard E Clark, Fotios Polydoros, Jane F Apperley, et al.
Pageof 9